KG2032-derived CAR T cells / Osaka University - LARVOL DELTA

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia (News-Medical) - "The team began screening thousands of mAbs raised against AML cells, narrowing this list down to 32 that bind specifically to AML cells. One mAb, named KG2032, clearly bound to AML cells in over 50% of patient samples tested. Using a sequencing strategy, the researchers determined that KG2032 bound to HLA-DRB1...The KG2032 CAR T cells displayed strong and specific anti-AML effects in vitro with cell culture experiments, as well as in vivo with a mouse model. The treated mice did not display any overt signs of toxicity. Engineered cord blood-derived CAR natural killer (NK) cells showed similar results."

Preclinical • Acute Myelogenous Leukemia